Keryx Biopharmaceuticals announced results from the Phase 2 study of Zerenex (ferric citrate) for the treatment of hyperphosphatemia in patients with end-stage renal disease (ESRD) on thrice weekly hemodialysis.
Your search for esrd returned 57 results
Screening not linked to improved patient survival after transplant; may delay time to listing, transplant
In U.S. dialysis centers treating end-stage renal (ESRD) patients with methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia, vancomycin is overprescribed, despite evidence of lower rates of hospitalization and death in cefazolin-treated patients.
Few new end-stage renal disease (ESRD) patients are referred for kidney transplant evaluation within one year of starting treatment, although referral practices vary considerably.
Declines in the estimated glomerular filtration rate offer an earlier end point for studying the progression of chronic kidney disease.
Shorter sleep duration, greater sleep fragmentation linked to greater decline in eGFR
“CKD staged by level of eGFR and proteinuria characterizes the timeline of progression and can guide management strategies in children,” the authors write.
Keryx Biopharmaceuticals announced positive final data from its Phase 3 study of Zerenex (ferric citrate) for the treatment of hyperphosphatemia in end-stage renal disease (ESRD) patients on dialysis.
Women aren’t treated with dialysis as often as men when they have end-stage renal disease, according to new research.
Total of 26.6 and 27 percent of patients experienced anxiety, depression with initiation of RRT